Portal vein thrombosis (PVT) is a critical complication in liver cirrhosis (LC), significantly worsening portal hypertension and accelerating the progression to decompensation. Early identification of at-risk patients is paramount for improving prognosis. This review synthesizes current evidence, categorizing the risk factors for PVT-LC into four interconnected domains: hemodynamic disturbances, the severity of cirrhosis, vascular endothelial injury with hypercoagulable states, and thrombophilic genetic factors. By comprehensively delineating these elements and their predictive indicators, we provide a foundational framework for constructing clinically applicable prediction models to guide timely intervention.<\/p>\n
Introduction<\/p>\n
Liver cirrhosis represents the end-stage of chronic liver disease, with PVT emerging as a common and severe complication. Historically underdiagnosed, advances in imaging have revealed a PVT incidence ranging from 10% in compensated cirrhosis to over 25% in liver transplant candidates. PVT exacerbates portal hypertension, leading to refractory ascites, variceal bleeding, and hepatic encephalopathy. Its often insidious onset means many patients miss the optimal treatment window, underscoring the urgent need for proactive risk stratification and early prediction.<\/p>\n
1. Hemodynamic disturbance<\/p>\n
Hemodynamic alterations in the portal system are a cornerstone of PVT pathogenesis.\u00a0Decreased portal vein velocity (PVV), particularly below 15 cm\/s, is one of the most robust predictors, as it promotes blood stasis per Virchow’s triad.\u00a0Portal vein dilation (PVD > 14.5 mm)\u00a0further reduces flow velocity and can cause valve insufficiency and vortex formation, prolonging contact between clotting factors and the endothelium. Beyond the portal vein,\u00a0splenic vein dilation and decreased velocity\u00a0are critical, especially post-splenectomy, where thrombosis often initiates in the splenic vein before extending to the portal system.<\/p>\n
2. Vascular endothelial injury and hypercoagulable state<\/p>\n
This category encompasses iatrogenic, inflammatory, and metabolic insults that damage the endothelium and promote coagulation.<\/p>\n
\n\t
<\/p>\n
Iatrogenic interventions:\u00a0Splenectomy\u00a0is a major risk factor (increasing risk \u226510-fold), mediated by reduced portal flow, surgical trauma, and a post-operative rebound thrombocytosis.\u00a0Endoscopic therapies\u00a0for varices (ligation and sclerotherapy) also elevate PVT risk, likely by obstructing collateral flow and causing mechanical endothelial injury.<\/p>\n
\n\t
\n\t
<\/p>\n
Endotoxemia and inflammation<\/a>:\u00a0Systemic inflammation, often from bacterial translocation, can activate neutrophils and cytokines, damaging endothelium and triggering coagulation. Novel markers like the\u00a0neutrophil-to-lymphocyte ratio (NLR)\u00a0and\u00a0platelet-to-lymphocyte ratio (PLR)\u00a0show predictive promise. Emerging players include\u00a0phosphatidylserine-positive microparticles (PS+MPs)\u00a0and\u00a0neutrophil extracellular traps (NETs), which create a pro-thrombotic milieu.<\/p>\n
Metabolic syndrome:\u00a0Diabetes mellitus\u00a0is a well-established risk factor, inducing PVT through endothelial dysfunction and a hypercoagulable state. The roles of hypertension and abdominal obesity are also being explored.<\/p>\n
Coagulation-anticoagulation-fibrinolysis (CAF) biomarkers:\u00a0The hypercoagulable state in cirrhosis is uniquely reflected in specific biomarkers.\u00a0Elevated D-dimer (>0.87 \u03bcg\/mL)\u00a0is a key independent predictor. Rather than platelet count,\u00a0markers of platelet activation\u00a0like mean platelet volume (MPV) and P-selectin (CD62P) are more relevant. An imbalance between pro-coagulant\u00a0factor VIII\u00a0and anticoagulant\u00a0protein C, as well as a disrupted\u00a0von Willebrand factor (vWF)\/ADAMTS-13\u00a0ratio, are also significant predictive indicators.<\/p>\n
3. Severity of liver cirrhosis<\/p>\n The risk of PVT escalates with the progression of LC.<\/p>\n
Portal hypertension (PH) and its complications:\u00a0The severity of PH is a fundamental driver of PVT. A\u00a0hepatic venous pressure gradient (HVPG) \u2265 16-20 mmHg\u00a0is a strong predictor. Complications like\u00a0ascites, variceal hemorrhage, and hepatic encephalopathy\u00a0are all confirmed risk factors, with their presence indicating a higher likelihood of PVT.<\/p>\n
Liver metabolic function and scoring systems:\u00a0Laboratory markers of declining liver function, such as\u00a0low albumin, are associated with PVT. Composite scoring systems are highly useful; both\u00a0Child-Turcotte-Pugh (CTP) class B\/C\u00a0and higher\u00a0Model for End-Stage Liver Disease (MELD) scores\u00a0are independent predictors of PVT, reflecting the liver’s deteriorating ability to maintain coagulation balance.<\/p>\n
4. Mutations in thrombophilic genetic factors (THRGFs)<\/p>\n A subset of cirrhotic patients with PVT carries inherited pro-thrombotic mutations. Established genes include\u00a0Factor V Leiden,\u00a0prothrombin G20210A, and\u00a0MTHFR C677T. The\u00a0JAK2 V617F\u00a0mutation<\/a> is also significant, often indicating an underlying myeloproliferative neoplasm. A critical highlight is the\u00a0ethnic variation\u00a0in these factors; while FV Leiden and G20210A are common in Caucasians, mutations in genes like\u00a0PROC (Protein C)\u00a0may be more relevant in Asian populations. This necessitates the development of population-specific genetic screening algorithms.<\/p>\n Clinical decision-making and conclusions<\/p>\n The review culminates in a practical\u00a0risk stratification framework\u00a0(Table 4) and a\u00a0clinical algorithm for early screening . High-risk factors (e.g., splenectomy history, low PVV) and medium-risk factors (e.g., diabetes, high D-dimer, CTP B\/C) are identified, guiding the frequency of ultrasound surveillance and consideration of anticoagulation.<\/p>\n In conclusion, PVT in cirrhosis arises from a complex interplay of hemodynamic, cirrhotic severity, hypercoagulable, and genetic factors. These elements are not isolated but interact and reinforce each other. Future research must focus on validating novel biomarkers, establishing precise cutoff values for predictive indicators, and constructing integrated models that can be seamlessly applied in clinical practice to enable pre-emptive management and improve patient outcomes.<\/p>\n Source:<\/p>\n Journal reference:<\/p>\n
\n\t
\n\t
<\/p>\n
\n
\n
\n\t
\n\t
<\/p>\n
\n\t
<\/p>\n
\n\t
<\/p>\n
\n\t
\n\t
<\/p>\n
\n\t
<\/p>\n